NEI Prescribe vs BMC MAT Quick Start
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
NEI Prescribe
This point-of-care resource aids in medication selection for psychiatric drugs. It provides comprehensive prescribing information for over 150 medications for adults, children, and adolescents, with interactive filters for customized patient-specific lists.
- Full prescribing details for 140+ psychiatric drugs
- Interactive medication filter
- Search by drug name or diagnosis
- Toggle between adult and pediatric libraries
- Offline access to content
- Always up to date
Read full descriptionHide full description
The most powerful tool for your prescribing arsenal is here. NEI Prescribe is a point of care resource that facilitates medication selection. Access full prescribing information for adults, children, and adolescents, including expert tips and pearls, for more than 150 psychiatric drugs. Apply the filter to create a customized list of possible medications to review based on your preferences for a particular patient. Quickly and easily find the prescribing details you need by using the navigation menu and user-friendly icons. NEI Prescribe features: • Full prescribing details for more than 140 psychiatric drugs • Interactive filter for quickly identifying medications that may fit your patient's needs • Search for medications by drug name or diagnosis/use • Use switch above search field to toggle between library for adults or children and adolescents • Dynamic and screen-friendly presentation of content • Simple, fast, and always up to date • Internet or Wi-Fi connection not required for use of the app (Internet connection required for updates)
BMC MAT Quick Start
This app provides healthcare providers with evidence-based guidance for treating opioid and alcohol use disorders. It offers step-by-step clinical decision trees and resources for initiating medications like buprenorphine and naltrexone, and managing pain in patients on these treatments.
- Buprenorphine initiation guides
- Naltrexone initiation guides
- Pain management protocols
- Clinical decision trees
- Medication withdrawal symptom management
- Patient messaging tools
Read full descriptionHide full description
This app offers healthcare providers the latest evidence-based guidance for treating opioid and alcohol use disorders (OUD and AUD) assisting in the initiation of medications such as buprenorphine and naltrexone. This is an essential tool for those starting patients on these medications, providing step-by-step clinical decision trees and valuable resources for managing not only AUD and OUD but acute and chronic pain for patients already on buprenorphine or naltrexone. With interactive tools, treatment protocols, and patient messaging features, this app empowers clinicians to deliver life-saving care while improving while improving treatment outcomes for substance use disorders. More than 46 million people aged 12 or older (or 16.5% of the US population) met the DSM-5 criteria for having a substance use disorder (SUD) in the past year based on the latest data from the 2021 National Survey on Drug Use and Health (NSDUH). However, only about 6% of people received any treatment for their SUD. Providing addiction treatment, including the use of FDA- approved medications and behavioral health therapies, has been shown to save lives and increase retention in treatment. The interactive clinical algorithms in this app walk you through each step of the clinical decision- making process to help you care for patients with an OUD or AUD. The clinical algorithms are also available in PDF format for easy viewing along with ability to securely text message patient tools to get started on buprenorphine. Additionally, several other clinical tools and resources related to SUD are included. BMC MAT QUICK START FEATURES: CLINICAL ALGORITHMS * Buprenorphine Initiation Guide: Decision trees for starting patients with an opioid use disorder on buprenorphine who are not currently physically dependent on opioids, opioid-dependent and not yet in withdrawal, and opioid-dependent and in active withdrawal. * Initiation of Extended-Release Injectable Buprenorphine: Guidance for starting a patient on new weekly and monthly formation formulations of extended-release injectable buprenorphine. * Naltrexone Initiation for Alcohol Use Disorder: Guidance for starting a patient on naltrexone for the treatment of alcohol use disorder. * Naltrexone Initiation for Opioid Use Disorder: Guidance for starting a patient on naltrexone for the treatment of opioid use disorder. Includes strategies for managing opioid withdrawal during the required “washout period” prior to starting naltrexone and avoiding precipitated withdrawal. * Pain Management While on Buprenorphine for Opioid Use Disorder: Guidance for managing acute and chronic pain in patients already on buprenorphine for opioid use disorder. * Pain Management While on Naltrexone: Guidance for managing acute pain (both anticipated and unanticipated) and chronic pain in patients already on naltrexone for opioid use disorder. * New! List of medication classes to assist in the management of opioid withdrawal symptoms. CLINICAL TOOLS * DSM-5 criteria for diagnosis of an opioid use disorder * Clinical Opiate Withdrawal Scale (COWS) to measure the severity of opioid withdrawal * Alcohol Use Disorders Identification Test (AUDIT-C) to identify risky drinking patterns PATIENT HANDOUTS * Buprenorphine Initiation Guide: A guide to give to patients who are starting buprenorphine in the home or community setting. Note: This app is designed exclusively for the use of healthcare providers. This app is not intended for use to diagnose a disease or to cure, mitigate, treat, or prevent any condition or disease. It is the responsibility of the treating clinician to rely on their own experience and knowledge about their specific patient to determine dosages and the best treatment for that patient.
Screenshots
Verdict
The clearest difference is rating: BMC MAT Quick Start at 5.0 against NEI Prescribe's 4.1. BMC MAT Quick Start also leads on iOS requirement (13.6 vs 15.6). NEI Prescribe's advantage is update cadence (every 4 months vs every 11 months). On price, ratings volume, ads and in-app purchases there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
BMC MAT Quick Start holds the better App Store score, 5.0 against 4.1. Both are backed by a comparable volume of ratings — 37 and 28 respectively.
NEI Prescribe ships an update every 4 months, BMC MAT Quick Start every 11 months. The most recent releases landed on November 19, 2026 and November 16, 2026 respectively.
| Parameter | NEI Prescribe | BMC MAT Quick Start |
|---|---|---|
| Price | Free | Free |
| Rating | 4.1 (37 ratings) | 5.0 (28 ratings) — better |
| Positive reviews | 52.6% of reviews | — |
| Number of ratings | 37 — better | 28 |
| Update frequency | Every 4 months — better | Every 11 months |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 15.6 | 13.6 — better |
| Further details — not scored | ||
| Size | 14 MB | 29 MB |
| Age rating | 17+ | 17+ |
| Developer | Neuroscience Education Institute, LLC | Boston Medical Center Corporation |
Customer experience
NEI Prescribe
BMC MAT Quick Start
In-app purchases
NEI Prescribe
No in-app purchases
BMC MAT Quick Start
No in-app purchases
Questions
Is NEI Prescribe free?
Is BMC MAT Quick Start free?
Which has better reviews, NEI Prescribe or BMC MAT Quick Start?
Do NEI Prescribe or BMC MAT Quick Start have ads?
Which is updated more often, NEI Prescribe or BMC MAT Quick Start?
Other comparisons















